Small Molecule Pharmaceutical Sciences, ‡Protein Analytical Chemistry, and §Late Stage Pharmaceutical and Process Development, Genentech , 1 DNA Way, South San Francisco, California 94080, United States.
Anal Chem. 2014 May 20;86(10):5150-7. doi: 10.1021/ac5009628. Epub 2014 May 2.
Polysorbate 20 is a nonionic surfactant commonly used in the formulation of therapeutic monoclonal antibodies (mAb) to prevent protein denaturation and aggregation. It is critical to understand the molecular heterogeneity and stability of polysorbate 20 in mAb formulations as polysorbate can gradually degrade in aqueous solution over time by multiple pathways losing surfactant functions and leading to protein aggregation. The molecular heterogeneity of polysorbate and the interference from proteins and the excipient in the formulation matrix make it a challenge to study polysorbate in protein formulations. In this work, the characterization and stability study of polysorbate 20 in the presence of mAb formulation sample matrix is first reported using two-dimensional liquid chromatography (2DLC) coupled with charged aerosol detection (CAD) and mass spectrometry (MS) detection. A mixed-mode column that has both anion-exchange and reversed-phase properties was used in the first dimension to separate protein and polysorbate in the formulation sample, while polysorbate 20 esters were trapped online and then analyzed using an reversed-phase ultrahigh-performance liquid chromatography (RP-UHPLC) column in the second dimension to further separate the ester species. The MS served as the third dimension to further resolve as well as to identify the polysorbate ester subspecies. Another 2DLC method using a cation-exchange column in the first dimension and the same RP-UHPLC method in the second dimension was developed to analyze the degradation products of polysorbate 20. Stability samples of a protein drug product were studied using these two 2DLC-CAD-MS methods to separate, identify, and quantify the multiple ester species in polysorbate 20 and also to monitor the change of their corresponding degradants. We found different polysorbate esters degrade at different rates, and importantly, the degradation rates for some esters are different in the protein formulation compared to a placebo that has no protein. The multidimensional UHPLC-CAD-MS approach provides insights into the heterogeneous stability behaviors of polysorbate 20 subspecies in real-time stability samples of a mAb formulation.
聚山梨酯 20 是一种非离子表面活性剂,常用于治疗性单克隆抗体 (mAb) 的配方中,以防止蛋白质变性和聚集。了解 mAb 配方中聚山梨酯 20 的分子异质性和稳定性至关重要,因为聚山梨酯随着时间的推移会通过多种途径逐渐降解在水溶液中,失去表面活性剂功能并导致蛋白质聚集。聚山梨酯的分子异质性以及配方基质中的蛋白质和赋形剂的干扰,使得研究蛋白质配方中的聚山梨酯具有挑战性。在这项工作中,首次报道了使用二维液相色谱 (2DLC) 与带电气溶胶检测 (CAD) 和质谱 (MS) 检测相结合,对 mAb 制剂样品基质中聚山梨酯 20 的特性和稳定性进行研究。在第一维中使用具有阴离子交换和反相性质的混合模式柱分离配方样品中的蛋白质和聚山梨酯,同时在线捕获聚山梨酯 20 酯,然后在第二维中使用反相超高效液相色谱 (RP-UHPLC) 柱进行分析,以进一步分离酯类。MS 作为第三维,进一步分离和鉴定聚山梨酯酯亚类。还开发了另一种使用第一维阳离子交换柱和第二维相同 RP-UHPLC 方法的 2DLC-CAD-MS 方法,以分析聚山梨酯 20 的降解产物。使用这两种 2DLC-CAD-MS 方法研究了一种蛋白质药物产品的稳定性样品,以分离、鉴定和定量聚山梨酯 20 中的多种酯类,并监测其相应降解产物的变化。我们发现不同的聚山梨酯酯以不同的速率降解,重要的是,与不含蛋白质的安慰剂相比,一些酯在蛋白质制剂中的降解速率不同。多维 UHPLC-CAD-MS 方法为实时 mAb 制剂稳定性样品中聚山梨酯 20 亚类的异质稳定性行为提供了深入了解。